Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201093 · ClinicalTrials.gov registry record · Phase 3
Fixed-Dose Trial in Early Parkinson's Disease (PD)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 529
- Enrollment target
NCT04201093 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 529 participants.
The verdict
NCT04201093, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 529 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
Interventions
- DRUG Placebo
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 529 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201093
The ClinicalTrials.gov registry entry for NCT04201093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 529 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04201093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04201093 about?
NCT04201093 is a clinical study titled "Fixed-Dose Trial in Early Parkinson's Disease (PD)". The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
What is the current status of trial NCT04201093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 529 participants. The study started on 2019-12-13. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT04201093?
The interventions under investigation include: Placebo (DRUG), Tavapadon (DRUG).
Who is sponsoring clinical trial NCT04201093?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.